全文获取类型
收费全文 | 1281篇 |
免费 | 6篇 |
国内免费 | 1篇 |
专业分类
化学工业 | 6篇 |
金属工艺 | 1篇 |
机械仪表 | 5篇 |
建筑科学 | 3篇 |
能源动力 | 2篇 |
水利工程 | 2篇 |
无线电 | 2篇 |
一般工业技术 | 9篇 |
冶金工业 | 1255篇 |
自动化技术 | 3篇 |
出版年
2020年 | 1篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2015年 | 2篇 |
2013年 | 3篇 |
2011年 | 1篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2004年 | 2篇 |
2003年 | 2篇 |
1999年 | 43篇 |
1998年 | 407篇 |
1997年 | 208篇 |
1996年 | 147篇 |
1995年 | 80篇 |
1994年 | 54篇 |
1993年 | 78篇 |
1992年 | 6篇 |
1991年 | 17篇 |
1990年 | 19篇 |
1989年 | 13篇 |
1988年 | 24篇 |
1987年 | 16篇 |
1986年 | 13篇 |
1985年 | 8篇 |
1983年 | 3篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 1篇 |
1978年 | 7篇 |
1977年 | 24篇 |
1976年 | 60篇 |
1975年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有1288条查询结果,搜索用时 15 毫秒
21.
Teri Linda; Truax Paula; Logsdon Rebecca; Uomoto Jay; Zarit Steven; Vitaliano Peter P. 《Canadian Metallurgical Quarterly》1992,7(4):622
The Revised Memory and Behavior Problems Checklist (RMBPC), a 24-item, caregiver-report measure of observable behavioral problems in dementia patients, provides 1 total score and 3 subscale scores for S problems (memory-related, depression, and disruptive behaviors) and parallel scores for caregiver reaction. Data were obtained from 201 geriatric Ss and their caregivers. Factor analysis confirmed 3 1st-order factors, consistent with subscales just named, and 1 general factor of behavioral disturbance. Overall scale reliability was good, with alphas of .84 for S behavior and .90 for caregiver reaction. Subscale alphas ranged from .67 to .89. Validity was confirmed through comparison of RMBPC scores with well-established indexes of depression, cognitive impairment, and caregiver burden. The RMBPC is recommended as a reliable and valid tool for the clinical and empirical assessment of behavior problems in dementia Ss. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献
22.
23.
24.
CG Moertel TR Fleming JS Macdonald DG Haller JA Laurie 《Canadian Metallurgical Quarterly》1993,11(12):2386-2390
PURPOSE: To determine the frequency and nature of hepatic toxicity associated with fluorouracil (5-FU) plus levamisole adjuvant therapy. PATIENTS AND METHODS: All patients had resection of stage II or stage III colon cancer and were randomized to receive observation only, levamisole alone, or 5-FU plus levamisole. Serial liver function studies were documented in 1,025 patients who did not develop recurrence during the year of therapy. RESULTS: One hundred forty-nine (39.6%) of 376 patients treated with 5-FU plus levamisole showed laboratory abnormalities consistent with hepatic toxicity, compared with 16.3% of 251 patients treated with levamisole alone and 16.1% of 398 untreated controls. Most common was elevation of alkaline phosphatase, frequently accompanied by elevations of transaminase or serum bilirubin. Characteristically, these changes were mild, not associated with symptoms, and resolved when therapy was stopped. In some instances, they were associated with elevated carcinoembryonic antigen (CEA) tests or with fatty liver seen on computed tomographic (CT) scan or liver biopsy. CONCLUSION: Mild and reversible hepatotoxicity is a common consequence of 5-FU plus levamisole adjuvant therapy, but this is only rarely symptomatic. However, the oncologist should be alert to this phenomenon, since the associated laboratory and imaging findings may simulate those associated with hepatic metastasis. 相似文献
25.
TR Smyth 《Canadian Metallurgical Quarterly》1994,20(1):27-36
The distribution of type I interleukin-1 receptor (IL-1R1) mRNA in the rat brain was examined by in situ hybridization technique. IL-1R1 mRNA was expressed in several brain regions including the anterior olfactory nucleus, medial thalamic nucleus, posterior thalamic nucleus, basolateral amygdaloid nucleus, ventromedial hypothalamic nucleus, arcuate nucleus, median eminence, mesencephalic trigeminal nucleus, motor trigeminal nucleus, facial nucleus and Purkinje cells of the cerebellum. Furthermore, we identified neuronal expression of IL-1R1 mRNA using simultaneous detection (double in situ hybridization) of IL-1R1 mRNA with neuron specific enolase mRNA. In addition to the expression in neuronal cells, IL-1R1 mRNA was also expressed on the vascular walls and the epithelial cells of the choroid plexus and the ventricles. These findings suggest the possibility that IL-1 produces its multiple effects on the central nervous system through the actions not only on neuronal cells but also on endothelial and epithelial cells. 相似文献
26.
TR Tripi 《Canadian Metallurgical Quarterly》1997,46(11):609-614
The case of a girl with Binder syndrome (maxillonasal-dysplasia) is reported. The girl has a peculiar face due to severely depressed nasal bridge, the nasofrontal angle is absent and the nose is hypoplastic with flattened alae and nasal tip; the upper lip has a convex contour with poorly developed philtrum. The premaxillary is hypoplastic. Lateral and postero-anterior cephalometric findings are presented. 相似文献
27.
28.
TR Kosten R Schottenfeld D Ziedonis J Falcioni 《Canadian Metallurgical Quarterly》1993,181(6):358-364
Buprenorphine at 2 mg and 6 mg daily was compared with methadone at 35 mg and 65 mg during 24 weeks of maintenance among 125 opioid-dependent patients. As hypothesized, 6 mg of buprenorphine were superior to 2 mg of buprenorphine in reducing illicit opioid use, but higher dosage did not improve treatment retention. Self-reported illicit opioid use declined substantially in all groups, but by the third month, significantly more heroin abuse was reported at 2 mg than at 6 mg of buprenorphine or of methadone. From an initial average of $1860/month, month 3 usage dropped to $41 (methadone 65 mg), $73 (methadone 35 mg), $118 (buprenorphine 6 mg), and $351/month (buprenorphine 2 mg). Days of use also dropped from 29 days to 1.7 (methadone 65 mg), 2.8 (methadone 35 mg), 4.0 (buprenorphine 6 mg), and 6.6 days/month (buprenorphine 2 mg). This relatively low efficacy for 2 mg of buprenorphine persisted through month 6 of the trial, with 7.2 days/month and $235/month of use for buprenorphine at 2 mg versus 1.9 days/month and $65/month for the other three groups. Increased opioid abuse also was associated with significantly greater and persistent opioid withdrawal symptoms. Our secondary hypothesis, that buprenorphine would be equivalent to methadone in efficacy, was not supported. Treatment retention was significantly better on methadone (20 vs. 16 weeks), and methadone patients had significantly more opioid-free urines (51% vs. 26%). Abstinence for at least 3 weeks was also more common on methadone than buprenorphine (65% vs. 27%).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
29.
30.